首页> 外文期刊>Therapeutic Drug Monitoring >Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions.
【24h】

Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions.

机译:使用新的食品和药物管理效力指南在空腹条件下健康志愿者中制备的左甲状腺素钠软胶囊的药代动力学等效性。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To assess the pharmacokinetic equivalence of a new soft capsule formulation of levothyroxine versus a marketed reference product and to assess the soft capsule formulated with stricter potency guidelines versus the capsule before the implementation of the new potency rule. METHOD: Two single-dose randomized two-way crossover pharmacokinetic equivalence studies and one dosage form proportionality single-dose study comparing low, medium, and high strengths of the new formulation. All three studies were performed in a clinical setting. Participants were healthy male and female adult subjects with normal levothyroxine levels. A total of 90 subjects participated in the three studies. RESULTS: Pharmacokinetic parameters were calculated on baseline- adjusted concentrations. The first pharmacokinetic equivalence study compared the levothyroxine sodium soft capsule formulation (Tirosint) with the reference Synthroid tablets and the two products were considered bioequivalent. The dosage form proportionality study compared the 50-, 100-, and 150-mug test capsules strengths dosed at the same level (600 mug) and all three strengths were considered equivalent when given at the same dosage. The last study compared the test capsule used in the first two studies with a new capsule formulation following the new potency guideline (+/-5%) set forward by the Food and Drug Administration and the two capsules were considered bioequivalent. Doses were well tolerated by subjects in all three studies with no serious adverse events reported. CONCLUSIONS: The levothyroxine soft capsule formulated with the stricter new potency guideline set forward by the Food and Drug Administration met equivalence criteria in terms of rate and extent of exposure under fasting conditions to the reference tablet formulation. Clinical doses of the capsule formulation can be given using any combination of the commercialized strengths.
机译:目的:评估新的左甲状腺素软胶囊制剂与市售参考产品的药代动力学等效性,并评估在实施新的效力规则之前,相对于胶囊使用更严格的效力指南配制的软胶囊。方法:两项单剂量随机两通交叉药代动力学等效性研究和一项剂型比例单剂量研究比较了新制剂的低,中和高强度。所有这三项研究都是在临床环境中进行的。参与者是具有正常左甲状腺素水平的健康男性和女性成年受试者。共有90名受试者参加了这三项研究。结果:药代动力学参数是在基线调整浓度下计算的。首次药代动力学等效研究比较了左甲状腺素钠软胶囊制剂(Tirosint)与参考Synthroid片剂,认为这两种产品具有生物等效性。剂型比例研究比较了以相同水平(600杯)给药的50、100和150杯测试胶囊的强度,当以相同剂量给药时,所有三种强度均被认为是等效的。上一项研究将前两次研究中使用的测试胶囊与遵循美国食品药品管理局提出的新效能指南(+/- 5%)的新胶囊配方进行了比较,并且认为这两种胶囊具有生物等效性。在所有三项研究中,受试者对剂量的耐受性均良好,未报告严重不良事件。结论:根据食品和药物管理局提出的更严格的新效能指南配制的左甲状腺素软胶囊在禁食条件下与参考片剂的接触率和程度方面达到了等效标准。胶囊制剂的临床剂量可以使用商业强度的任何组合给予。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号